EE+ POEM Archive
Abrocitinib and upadacitinib likely to be most effective immunomodulators for atopic dermatitis, but very expensive
Abrocitinib and upadacitinib likely to be most effective immunomodulators for atopic dermatitis, but very expensive is a topic covered in the EE+ POEM Archive.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Abrocitinib and Upadacitinib Likely to Be Most Effective Immunomodulators for Atopic Dermatitis, but Very Expensive." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315721/all/Abrocitinib_and_upadacitinib_likely_to_be_most_effective_immunomodulators_for_atopic_dermatitis__but_very_expensive.
Abrocitinib and upadacitinib likely to be most effective immunomodulators for atopic dermatitis, but very expensive. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315721/all/Abrocitinib_and_upadacitinib_likely_to_be_most_effective_immunomodulators_for_atopic_dermatitis__but_very_expensive. Accessed January 27, 2023.
Abrocitinib and upadacitinib likely to be most effective immunomodulators for atopic dermatitis, but very expensive. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315721/all/Abrocitinib_and_upadacitinib_likely_to_be_most_effective_immunomodulators_for_atopic_dermatitis__but_very_expensive
Abrocitinib and Upadacitinib Likely to Be Most Effective Immunomodulators for Atopic Dermatitis, but Very Expensive [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2023 January 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315721/all/Abrocitinib_and_upadacitinib_likely_to_be_most_effective_immunomodulators_for_atopic_dermatitis__but_very_expensive.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Abrocitinib and upadacitinib likely to be most effective immunomodulators for atopic dermatitis, but very expensive
ID - 1315721
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1315721/all/Abrocitinib_and_upadacitinib_likely_to_be_most_effective_immunomodulators_for_atopic_dermatitis__but_very_expensive
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
